Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3440736 | 0.84 | MAPT (0.46) | CHRM4SMN1; SMN2SUV39H2HRH3L3MBTL1 | |
| SCHEMBL22837815 | 0.84 | CHRM4 (0.52) | CHRM4HRH3DRD2DRD3CHRM2 | |
| SCHEMBL22837879 | 0.84 | HRH3 (0.40) | CHRM4SUV39H2HRH3LTA4HL3MBTL3 | |
| SCHEMBL26641521 | 0.79 | MAPT (0.45) | HRH3LTA4HL3MBTL3L3MBTL1AKR1C3 | |
| SCHEMBL10118638 | 0.79 | MEN1 (0.53) | SMN1; SMN2HRH3 | |
| SCHEMBL26641377 | 0.76 | CDK4 (0.43) | CHRM4LTA4HDRD2DRD3CHRM2 | |
| SCHEMBL27364511 | 0.76 | DRD2 (0.44) | DRD2DRD3 | |
| SCHEMBL2267493 | 0.76 | MAPT (0.41) | CHRM4SMN1; SMN2HRH3L3MBTL1 | |
| SCHEMBL14862764 | 0.75 | LTA4H (0.45) | SMN1; SMN2HRH3LTA4HL3MBTL3L3MBTL1 | |
| SCHEMBL22837830 | 0.75 | HTR2A (0.43) | SMN1; SMN2LTA4HL3MBTL3L3MBTL1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | CHEK1, CHEK2, CDK1 | CHRM4 3273/4885SMN1; SMN2 3616/4885SUV39H2 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.